Skip to content
DataLookout
Menu

NeoMega-REALNCT07944638

Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Severe retinopathy of prematurity (ROP)
Timeframe: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age

Secondary (8)

Treated retinopathy of prematurity (ROP)
Any retinopathy of prematurity (ROP)
Bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age, by Jensen grade
BPD or death before 36 weeks postmenstrual age (composite)
Necrotizing enterocolitis (NEC)
Show 3 moreShow less
Surgical necrotizing enterocolitis (NEC)
NEC or death before discharge (composite)
Death before discharge

Arms and interventions

Historical period (before NeoMega36 implementation)

Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period before NeoMega36 was introduced into routine care at that unit (European units: preferably 24 months, not overlapping the NeoMega period; Sweden: a defined period before national implementation). Infants received standard nutrition according to local practice.

NeoMega period (after NeoMega36 implementation)

Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period after NeoMega36 was introduced into routine care at that unit (European units: at least 12 months; Sweden: from national implementation in 2026). All eligible infants in this period are analysed in this group whether or not they individually received NeoMega36; the numbers given and not given the supplement are reported only to describe uptake.

Dietary supplements: Enteral arachidonic acid and docosahexaenoic acid supplement

Sites

1 site in 1 country

  • Sahlgrenska Academy, University of GothenburgGothenburg, Sweden